Tumor necrosis factor-α antagonists and neuropathy

Muscle and Nerve

Volumn 37, Issue 3, 2008, Pages 281-292

  Stübgen, Joerg Patrick ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Neuropathy; TNF ; TNF antagonists

Indexed keywords

ADALIMUMAB; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; MYELIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ATAXIA; AXONAL SENSORIMOTOR POLYNEUROPATHY; DEMYELINATING NEUROPATHY; DRUG EFFECT; DYSARTHRIA; FEMORAL NEUROPATHY; GUILLAIN BARRE SYNDROME; HUMAN; ISCHEMIA; LEUKOCYTOCLASTIC VASCULITIS; MACROPHAGE; MONONEUROPATHY MULTIPLEX; MOTOR NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY WITH CONDUCTION BLOCK; NERVE BLOCK; NERVE FIBER; NEUROPATHY; PATHOGENESIS; PLASMAPHERESIS; POLYNEUROPATHY; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; T LYMPHOCYTE; VASCULITIS;

ANTI-INFECTIVE AGENTS; HUMANS; MODELS, BIOLOGICAL; POLYNEUROPATHIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39749167232     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20924     Document Type: Review

References (91)

1. Alldred A. Etanercept in rheumatoid arthritis. Expert Opin Pharmacother 2001;1:1137-1148.
2. Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. J Rheumatol 2005;32:759-760.
3. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884.
4. Beutler B. Tumor necrosis factors: the molecules and their emerging role in medicine. New York: Raven Press; 1992. 590 p.
5. Birnbaum G, Antel J, Hartung H-P. Introduction to immunology. In: Antel J, Birnbaum G, Hartung H-P, Vincent A, editors. Clinical neuroimmunology. Oxford: Oxford University Press; 2006. p 1-11.
6. Birnbaum J. Inflimab-associated neuropathy in RA patients - the importance of considering the diagnosis of mononeuritis multiplex. Clin Rheumatol 2007;26:281-282.
7. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285.
8. Bronan CF, Litwak MS, Schroeder CE, Selmaj K, Raine CS, Arezzo JC. Preliminary studies of cytokine-induced functional effects of the visual pathways in the rabbit. J Neuroimmunol 1989;25:227-239.
9. Carpo M, Nobile-Orazio E, Meucci N, Gamba M, Barbieri S, Allaria S, et al. Anti-GD1a ganglioside antibodies in peripheral motor syndromes. Ann Neurol 1996;39:539-543.
10. Chin RL, Sherman WH, Sander HW, Hays AP, Latov N. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003;210:19-21.
11. Cisternas M, Gutiérrez M, Jacobelli S. Successful rechallenge with anti-tumor necrosis factorα for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. Arthritis Rheum 2002;46:3107-3109.
12. Cocito D, Bergamasco B, Tavella A, Poglio F, Paolasso I, Cosla P, et al. Multifocal motor neuropathy during treatment with infliximab. J Peripher Nerv Syst 2005;10:386-387.
13. Cope A, Etranger R, McDevitt H. The role of TNF-α and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 1997;148:307-312.
14. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD. Chronic tumor necrosis factor alter T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185: 1573-1584.
15. Corse AM, Chaudry V, Crawford TO, Cornblath DR, Kuncl RW, Griffin JW. Sensory nerve pathology in multifocal motor neuropathy. Ann Neurol 1996;39:319-325.
16. Créange A, Bélec L, Clair B, Raphael JC, Gherardi RK. Circulating tumor necrosis factor (TNF)-α and soluble TNF-α receptors in patients with Guillain-Barré syndrome. J Neuroimmunol 1996;68:95-99.
17. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002;47:445-449.
18. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev 2000;174:160-171.
19. Enbrel (etanercept). Current prescribing information. In: Physicians' desk reference. Montvale, NJ: Thompson; 2007. p 584-591.
20. Feagan BG, Enns R, Fedorak RN, Panaccione R, Pare P, Steinhart AH, et al. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can J Clin Pharmacol 2001;8:188-198.
21. Galaria N, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000;27:2041-2044.
22. Gold R, Hartung H-P, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000;6:88-91.
23. Guillevin L, Mouthon L. Tumor necrosis factor alpha blockade and risk of vasculitis. J Rheumatol 2004;31:1885-1887.
24. Hall SM, Redford EJ, Smith KJ. Tumor necrosis factor-α has few morphological effects within the dorsal columns of the spinal cord, in contrast to its effects in the peripheral nervous system. J Neuroimmunol 2000;106:130-136.
25. Hamilton K, Clair EW. Tumor necrosis factor-alpha blockade: a new era for the effective management of rheumatoid arthritis. Expert Opin Pharmacother 2000;1:1041-1052.
26. Hartung H-P. Immune-mediated demyelination. Ann Neurol 1993;33:563-567.
27. Hartung HP, Jung S, Stoll, Zielasek J, Schmidt B, Archelos JJ, et al. The role of inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 1992;40:197-210.
28. Hughes RAC. The concept and classification of Guillain-Barré syndrome and related disorders. Rev Neurol (Paris) 1995;151:291-294.
29. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61:736-740.
30. HUMIRA (adalimumab). Current prescribing information. In: Physicians' desk reference. Montvale, NJ: Thompson; 2007. p 466-471.
31. Jarand J, Zochodne DW, Martin LO, Voll C. Neurological complications of infliximab. J Rheumatol 2006;33:1018-1020.
32. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-α therapy-induced vasculitis: case series. J Rheumatol 2003;30:2287-2291.
33. Kaji R, Oka N, Tsuji T, Mezaki T, Nishio T, Akiguchi I, et al. Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol 1993;33:152-158.
34. Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001;193:427-434.
35. Kieseier BC, Clements JM, Pischel HB, Wells GM, Miller K, Gearing AJ, et al. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol 1998;43:427-434.
36. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung H-P. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004;30:131-156.
37. Kieseier BC, Krivacic K, Jung S, Pischel H, Toyka KV, Ransohoff RM, et al. Sequential expression of chemokines in experimental autoimmune neuritis. J Neuroimmunol 2000;110: 121-129.
38. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The role of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Ann Rheum Dis 1999;58(suppl 1):32-39.
39. Latov N, Sherman WH. Improvement with etanercept (Enbrel) in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2000;48:473.
40. Liu J, Marino MW, Wong G. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4:78-83.
41. Livermore PA, Murray KJ. Anti tumor necrosis factor therapy associated with cutaneous vasculitis. Rheumatology 2002;41: 1450-1452.
42. Lock C, Oksenberg J, Steinman L. The role of TNFα and lymphotoxin in demyelinating disease. Ann Rheum Dis 1999; 58(suppl 1):121-128.
43. Mathey EK, Pollard JD, Armati PJ. TNF alpha, IFN gamma, and IL-2 mRNA expression in CIDP sural nerve biopsies. J Neurol Sci 1999;163:47-52.
44. McCluskey L, Feinberg D, Cantor C, Bird S. "Pseudo-conduction block" in vasculitic neuropathy. Muscle Nerve 1999;22: 1361-1366.
45. Melendez-Vasquez C, Redford J, Choudhary PP, Gray IA, Maitland P, Gregson NA, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 1997;73:124-134.
46. Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000;43:243-249.
47. Misawa S, Kuwabara S, Mori M, Kawagushi N, Yoshiyama Y, Hattori T. Serum levels of tumor necrosis factor-α in chronic inflammatory polyneuropathy. Neurology 2001;56:666-669.
48. Mohan N, Edwards ET, Cupps TR, Oliviero PT, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-2869.
49. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004; 25:75-84.
50. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001;115:4-18.
51. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 2005;31:663-680.
52. Oh SJ, Claussen GC, Odabasi Z, Palmer CP. Multifocal demyelinating motor neuropathy: pathologic evidence of "inflammatory" demyelinating polyradiculoneuropathy." Neurology 1995;45:1828-1832.
53. Olney RK, Lewis RA, Putnam TD, Campellone JV. Consensus criteria for the diagnosis of multifocal motor neuropathy: American Association of Electrodiagnostic Medicine. Muscle Nerve 2003;27:117-121.
54. Pollard J. Chronic inflammatory demyelinating polyradiculoneuropathy. Curr Opin Neurol 2002;15:279-283.
55. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007;86: 242-251.
56. Redford FJ, Hall SM, Smith KJ. Vascular changes and demyelination induced by the intraneural injection of tumor necrosis factor. Brain 1995;118:869-878.
57. Remicade (infliximab). Current prescribing information. In: Physicians' desk reference. Montvale, NJ: Thompson; 2007. p 971-979.
58. Richette P, Dieudé P, Damiano J, Lacroix C, Lioté F, Orcel P, et al. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol 2004;31:2079-2081.
59. Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers. Neurology 2005;64:1468-1470.
60. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism. Arthritis Rheum 2001;44:1977-1983.
61. Rodino S, Sacca N, D'Amico T, Fragomeni A, Giglio A. Severe polyneuropathy complicating active Crohn's disease: rapid response to infliximab. Gut 2003;52:1070.
62. Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, Gonzalez C, Figueroa M. Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology 2005;44:132-133.
63. Said G, Hontebeyrie-Joskowicz M. Nerve lesions induced by macrophage activation. Res Immunol 1992;143:589-599.
64. Sandborn WJ, Targan SR. Biologic therapy for inflammatory bowel disease. Gastroenterology 2002;122:1592-1608.
65. Sandbrink F, Klion AD, Floeter MK. "Pseudo-conduction block" in a patient with vasculitic neuropathy. Electromyogr Clin Neurophysiol 2001;41:195-202.
66. Sander HW, Latov N. Research criteria for defining patients with CIDP. Neurology 2003;60(suppl):S8-S15.
67. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23: 339-346.
68. Seymour HE, Worsley JM, Smith JM, Thomas SHL. Anti-TNF agents for rheumatoid arthritis. Br J Clin Pharmacol 2001;51: 201-208.
69. Sharief MK, Ciardi M, Thompson EJ. Blood-brain barrier damage in patients with bacterial meningitis: association with tumor necrosis factor-alpha but not interleukin-1beta. J Infect Dis 1992;166:350-358.
70. Sharief MK, Ingram DA, Swash M. Circulating tumor necrosis factor-α correlates with electrodiagnostic abnormalities in Guillain-Barré syndrome. Ann Neurol 1997;42:68-73.
71. Sharief MK, Ingram DA, Swash DA, Thompson EJ. IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 1999;52:1833-1838.
72. Sharief MK, McLean B, Thompson EJ. Elevated serum levels of tumor necrosis factor-α in Guillain-Barré syndrome. Ann Neurol 1993;33:591-596.
73. Shin I-S J, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factorα antagonist therapy. Arthritis Rheum 2006;54:1429-1434.
74. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-1888.
75. Singer OC, Otto B, Steinmetz H, Ziemann U. Acute neuropathy with multiple conduction blocks after TNFα monoclonal antibody therapy. Neurology 2004;63:1754.
76. Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst 2001;6:67-72.
77. Sorkin LS, Doom CM. Epineural application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J Peripher Nerv Syst 2000;5:96-100.
78. Stoll G, Jung S, Jander S, van der Meide P, Hartung HP. Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol 1993;45:175-182.
79. Taylor BV, Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 2000;23:900-908.
80. Terenghi F, Allaria S, Nobile-Orazio E. Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy. J Periph Nerv Syst 2006; 11:67-71.
81. Tektonidou MG, Serelis J, Skopouli FN. Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol 2007;26:258-260.
82. The WGET research group. The Wegener's Granulomatosis Etanercept Trial (WGET): randomized, double-masked, placebo-controlled trial of etanercept for the induction and maintenance of remission. Arthritis Rheum 2004;50(suppl): S1719.
83. Toyka KV, Hartung HP. Chronic inflammatory polyneuritis and neuropathies. Curr Opin Neurol 1996;9:240-250.
84. Tsang RS, Valdivieso-Garcia A. Pathogenesis of Guillain-Barré syndrome. Expert Rev And Infect Ther 2003;1:597-608.
85. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. Lancet Neurol 2005;4:309-319.
86. Van der Meché FG, Van Doorn PA, Meulstee J, Jennekens FG. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 2001;45:133-139.
87. Vasalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-452.
88. Wagner R, Janjigian M, Myers RR. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain 1998;74:35-42.
89. Weishaupt A, Bruck W, Hartung T, Toyka KV, Gold R. Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-α. Neurosci Lett 2001;306:77-80.
90. Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000;47:765-775.
91. Zhu J, Mix E, Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol 1998;84:40-52.